New pharmacological concepts for the treatment of iron overload disorders

Current Medicinal Chemistry

Volumn 16, Issue 5, 2009, Pages 576-590

  Mair, Sabine M ^a   Weiss, Guenter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anaemia; Divalent metal transporter 1; Erythropoietin; Ferroportin; Friedreich ataxia; Hemochromatosis; Hepcidin

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EBSELEN; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NIFEDIPINE; OMEPRAZOLE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IRON CHELATING AGENT;

ANEMIA; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; FERRITIN BLOOD LEVEL; FRIEDREICH ATAXIA; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; HYPERFERRITINEMIA; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON METABOLISM DISORDER; IRON OVERLOAD; IRON TRANSPORT; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; PATIENT COMPLIANCE; PHLEBOTOMY; REVIEW; RHEUMATOID ARTHRITIS; THALASSEMIA MAJOR; DIET; METABOLISM; PATHOPHYSIOLOGY;

DIET; HEMOCHROMATOSIS; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 63149173196     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458434     Document Type: Review

References (219)

1. Hentze, M.W.; Muckenthaler, M.U.; Andrews, N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell, 2004, 117, 285-297.
2. Weiss, G. Iron and immunity: A double-edged sword. Eur. J. Clin. Invest., 2002, 32 Suppl. 1, 70-78.
3. Andrews, N.C. Disorders of iron metabolism. N. Engl. J. Med., 1999, 341, 1986-1995.
4. Moura, E.; Noordermeer, M.A.; Verhoeven, N.; Verheul, A.F.; Marx, J.J. Iron release from human monocytes after erythrophagocytosis in vitro: An investigation in normal subjects and hereditary hemochromatosis patients. Blood, 1998, 92, 2511-2519.
5. Knutson, M.D.; Oukka, M.; Koss, L.M.; Aydemir, F.; Wessling-Resnick, M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc. Natl. Acad. Sci. USA, 2005, 102, 1324-1328.
6. Shayeghi, M.; Latunde-Dada, G.O.; Oakhill, J.S.; Laftah, A.H.; Takeuchi, K.; Halliday, N.; Khan, Y.; Warley, A.; McCann, F.E.; Hider, R.C.; Frazer, D.M.; Anderson, G.J.; Vulpe, C.D.; Simpson, R.J.; McKie, A.T. Identification of an intestinal heme transporter. Cell, 2005, 122, 789-801.
7. Nakai, Y.; Inoue, K.; Abe, N.; Hatakeyama, M.; Ohta, K.Y.; Otagiri, M.; Hayashi, Y.; Yuasa, H. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J. Pharmacol. Exp. Ther., 2007, 322, 469-476.
8. Poss, K.D.; Tonegawa, S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl. Acad. Sci. USA, 1997, 94, 10919-10924.
9. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin, Y.; Romero, M.F.; Boron, W.F.; Nussberger, S.; Gollan, J.L.; Hediger, M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature, 1997, 388, 482-488.
10. Fleming, M.D.; Trenor, C.C., 3rd; Su, M.A.; Foernzler, D.; Beier, D.R.; Dietrich, W.F.; Andrews, N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet., 1997, 16, 383-386.
11. McKie, A.T.; Barrow, D.; Latunde-Dada, G.O.; Rolfs, A.; Sager, G.; Mudaly, E.; Mudaly, M.; Richardson, C.; Barlow, D.; Bomford, A.; Peters, T.J.; Raja, K.B.; Shirali, S.; Hediger, M.A.; Farzaneh, F.; Simpson, R.J. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science, 2001, 291, 1755-1759
12. Gunshin, H.; Starr, C.N.; Direnzo, C.; Fleming, M.D.; Jin, J.; Greer, E.L.; Sellers, V.M.; Galica, S.M.; Andrews, N.C. Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. Blood, 2005, 106, 2879-2883.
13. Atanasova, B.; Mudway, I.S.; Laftah, A.H.; Latunde-Dada, G.O.; McKie, A.T.; Peters, T.J.; Tzatchev, K.N.; Simpson, R.J. Duodenal ascorbate levels are changed in mice with altered iron metabolism. J. Nutr., 2004, 134, 501-505.
14. Vulpe, C.D.; Kuo, Y.M.; Murphy, T.L.; Cowley, L.; Askwith, C.; Libina, N.; Gitschier, J.; Anderson, G.J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet., 1999, 21, 195-199.
15. Abboud, S.; Haile, D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem., 2000, 275, 19906-19912.
16. McKie, A.T.; Marciani, P.; Rolfs, A.; Brennan, K.; Wehr, K.; Barrow, D.; Miret, S.; Bomford, A.; Peters, T.J.; Farzaneh, F.; Hediger, M.A.; Hentze, M.W.; Simpson, R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell, 2000, 5, 299-309.
17. Donovan, A.; Brownlie, A.; Zhou, Y.; Shepard, J.; Pratt, S.J.; Moynihan, J.; Paw, B.H.; Drejer, A.; Barut, B.; Zapata, A.; Law, T.C.; Brugnara, C.; Lux, S.E.; Pinkus, G.S.; Pinkus, J.L.; Kingsley, P.D.; Palis, J.; Fleming, M.D.; Andrews, N.C.; Zon, L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature, 2000, 403, 776-781.
18. Wessling-Resnick, M. Iron imports. III. Transfer of iron from the mucosa into circulation. Am. J. Physiol. Gastrointest Liver Physiol., 2006, 290, G1-6.
19. Kakhlon, O.; Cabantchik, Z.I. The labile iron pool: Characterization, measurement, and participation in cellular processes(1). Free Radic. Biol. Med., 2002, 33, 1037-1046.
20. Ohgami, R.S.; Campagna, D.R.; Greer, E.L.; Antiochos, B.; McDonald, A.; Chen, J.; Sharp, J.J.; Fujiwara, Y.; Barker, J.E.; Fleming, M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet., 2005, 37, 1264-1269.
21. Dautry-Varsat, A.; Ciechanover, A.; Lodish, H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA, 1983, 80, 2258-2262.
22. Leimberg, M.J.; Prus, E.; Konijn, A.M.; Fibach, E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. J. Cell Biochem., 2008, 103, 1211-1218.
23. Brock, J.H. The physiology of lactoferrin. Biochem. Cell. Biol., 2002, 80, 1-6.
24. Kaplan, J. Mechanisms of cellular iron acquisition: Another iron in the fire. Cell, 2002, 111, 603-606.
25. Theurl, I.; Fritsche, G.; Ludwiczek, S.; Garimorth, K.; Bellmann-Weiler, R.; Weiss, G. The macrophage: A cellular factory at the interphase between iron and immunity for the control of infections. Biometals, 2005, 18, 359-367.
26. Hvidberg, V.; Maniecki, M.B.; Jacobsen, C.; Hojrup, P.; Moller, H.J.; Moestrup, S.K. Identification of the receptor scavenging hemopexin-heme complexes. Blood, 2005, 106, 2572-2579.
27. Kristiansen, M.; Graversen, J.H.; Jacobsen, C.; Sonne, O.; Hoffman, H.J.; Law, S.K.; Moestrup, S.K. Identification of the haemoglobin scavenger receptor. Nature, 2001, 409, 198-201
28. Weiss, G. Iron metabolism in the anaemia of chronic disease. Biochim. Biophys. Acta, 2008.
29. Muckenthaler, M.U.; Galy, B.; Hentze, M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr., 2008, 28, 197-213.
30. Muckenthaler, M.; Gray, N.K.; Hentze, M.W. IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol. Cell, 1998, 2, 383-388.
31. Rouault, T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol., 2006, 2, 406-414.
32. Drapier, J.C.; Hirling, H.; Wietzerbin, J.; Kaldy, P.; Kuhn, L.C. Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO J., 1993, 12, 3643-3649.
33. Weiss, G.; Goossen, B.; Doppler, W.; Fuchs, D.; Pantopoulos, K.; Werner-Felmayer, G.; Wachter, H.; Hentze, M.W. Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J., 1993, 12, 3651-3657.
34. Pantopoulos, K.; Hentze, M.W. Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J., 1995, 14, 2917-2924.
35. Schneider, B.D.; Leibold, E.A. Effects of iron regulatory protein regulation on iron homeostasis during hypoxia. Blood, 2003, 102, 3404-3411.
36. Haile, D.J.; Rouault, T.A.; Tang, C.K.; Chin, J.; Harford, J.B.; Klausner, R.D. Reciprocal control of RNA-binding and aconitase activity in the regulation of the iron-responsive element binding protein: Role of the iron-sulfur cluster. Proc. Natl. Acad. Sci. USA, 1992, 89, 7536-7540.
37. Yamanaka, K.; Ishikawa, H.; Megumi, Y.; Tokunaga, F.; Kanie, M.; Rouault, T.A.; Morishima, I.; Minato, N.; Ishimori, K.; Iwai, K. Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2. Nat. Cell Biol., 2003, 5, 336-340.
38. Hanson, E.S.; Rawlins, M.L.; Leibold, E.A. Oxygen and iron regulation of iron regulatory protein 2. J. Biol. Chem., 2003, 278, 40337-40342.
39. Parkkila, S.; Waheed, A.; Britton, R.S.; Bacon, B.R.; Zhou, X.Y.; Tomatsu, S.; Fleming, R.E.; Sly, W.S. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA, 1997, 94, 13198-13202.
40. Abouhamed, M.; Gburek, J.; Liu, W.; Torchalski, B.; Wilhelm, A.; Wolff, N.A.; Christensen, E.I.; Thevenod, F.; Smith, C.P. Divalent metal transporter 1 in the kidney proximal tubule is expressed in late endosomes/lysosomal membranes: Implications for renal handling of protein-metal complexes. Am. J. Physiol. Renal Physiol., 2006, 290, F1525-1533.
41. Canonne-Hergaux, F.; Gros, P. Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int., 2002, 62, 147-156.
42. Wareing, M.; Ferguson, C.J.; Green, R.; Riccardi, D.; Smith, C.P. In vivo characterization of renal iron transport in the anaesthetized rat. J. Physiol., 2000, 524 Pt 2, 581-586.
43. Wareing, M.; Ferguson, C.J.; Delannoy, M.; Cox, A.G.; McMahon, R.F.; Green, R.; Riccardi, D.; Smith, C.P. Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am. J. Physiol. Renal. Physiol., 2003, 285, F1050-1059.
44. Ludwiczek, S.; Theurl, I.; Muckenthaler, M.U.; Jakab, M.; Mair, S.M.; Theurl, M.; Kiss, J.; Paulmichl, M.; Hentze, M.W.; Ritter, M.; Weiss, G. Ca(2+) channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat. Med., 2007, 13, 448-454.
45. Ganz, T.; Nemeth, E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G199-203.
46. Pigeon, C.; Ilyin, G.; Courselaud, B.; Leroyer, P.; Turlin, B.; Brissot, P.; Loreal, O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem., 2001, 276, 7811-7819.
47. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306, 2090-2093.
48. Lesbordes-Brion, J.C.; Viatte, L.; Bennoun, M.; Lou, D.Q.; Ramey, G.; Houbron, C.; Hamard, G.; Kahn, A.; Vaulont, S. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood, 2006, 108, 1402-1405.
49. Nicolas, G.; Bennoun, M.; Porteu, A.; Mativet, S.; Beaumont, C.; Grandchamp, B.; Sirito, M.; Sawadogo, M.; Kahn, A.; Vaulont, S. Severe iron deficiency anaemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. USA, 2002, 99, 4596-4601.
50. Roy, C.N.; Mak, H.H.; Akpan, I.; Losyev, G.; Zurakowski, D.; Andrews, N.C. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anaemia of inflammation. Blood, 2007, 109, 4038-44.
51. De Domenico, I.; Ward, D.M.; Langelier, C.; Vaughn, M.B.; Nemeth, E.; Sundquist, W.I.; Ganz, T.; Musci, G.; Kaplan, J. The molecular mechanism of hepcidin-mediated ferroportin downregulation. Mol. Biol. Cell, 2007, 18, 2569-2578.
52. Detivaud, L.; Nemeth, E.; Boudjema, K.; Turlin, B.; Troadec, M.B.; Leroyer, P.; Ropert, M.; Jacquelinet, S.; Courselaud, B.; Ganz, T.; Brissot, P.; Loreal, O. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood, 2005, 106, 746-748.
53. Nemeth, E.; Rivera, S.; Gabayan, V.; Keller, C.; Taudorf, S.; Pedersen, B.K.; Ganz, T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest., 2004, 113, 1271-1276.
54. Kemna, E.; Pickkers, P.; Nemeth, E.; van der Hoeven, H.; Swinkels, D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 2005, 106, 1864-1866.
55. Lee, P.; Peng, H.; Gelbart, T.; Wang, L.; Beutler, E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc. Natl. Acad. Sci. USA, 2005, 102, 1906-1910.
56. Peyssonnaux, C.; Zinkernagel, A.S.; Datta, V.; Lauth, X.; Johnson, R.S.; Nizet, V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood, 2006, 107, 3727-3732.
57. Theurl, I.; Theurl, M.; Seifert, M.; Mair, S.; Nairz, M.; Rumpold, H.; Zoller, H.; Bellmann-Weiler, R.; Niederegger, H.; Talasz, H.; Weiss, G. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood, 2008, 111, 2392-2399.
58. Nicolas, G.; Chauvet, C.; Viatte, L.; Danan, J.L.; Bigard, X.; Devaux, I.; Beaumont, C.; Kahn, A.; Vaulont, S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest., 2002, 110, 1037-1044.
59. Peyssonnaux, C.; Zinkernagel, A.S.; Schuepbach, R.A.; Rankin, E.; Vaulont, S.; Haase, V.H.; Nizet, V.; Johnson, R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig., 2007, 117, 1926-1932.
60. Yoon, D.; Pastore, Y.D.; Divoky, V.; Liu, E.; Mlodnicka, A.E.; Rainey, K.; Ponka, P.; Semenza, G.L.; Schumacher, A.; Prchal, J.T. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J. Biol. Chem., 2006, 281, 25703-25711.
61. Choi, S.O.; Cho, Y.S.; Kim, H.L.; Park, J.W. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem. Biophys. Res. Commun., 2007, 356, 312-317
62. Silvestri, L.; Pagani, A.; Camaschella, C. Furin-mediated release of soluble hemojuvelin: A new link between hypoxia and iron homeostasis. Blood, 2008, 111, 924-931.
63. Nicolas, G.; Viatte, L.; Bennoun, M.; Beaumont, C.; Kahn, A.; Vaulont, S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis., 2002, 29, 327-335.
64. Braliou, G.G.; Verga Falzacappa, M.V.; Chachami, G.; Casanovas, G.; Muckenthaler, M.U.; Simos, G. 2-Oxoglutarate-dependent oxygenases control hepcidin gene expression. J. Hepatol., 2008, 48, 801-810.
65. Pietrangelo, A. Hemochromatosis: An endocrine liver disease. Hepatology, 2007, 46, 1291-1301.
66. Anderson, G.J.; Powell, L.W. HFE and non-HFE hemochromatosis. Int. J. Hematol., 2002, 76, 203-207.
67. Papanikolaou, G.; Samuels, M.E.; Ludwig, E.H.; MacDonald, M.L.; Franchini, P.L.; Dube, M.P.; Andres, L.; MacFarlane, J.; Sakellaropoulos, N.; Politou, M.; Nemeth, E.; Thompson, J.; Risler, J.K.; Zaborowska, C.; Babakaiff, R.; Radomski, C.C.; Pape, T.D.; Davidas, O.; Christakis, J.; Brissot, P.; Lockitch, G.; Ganz, T.; Hayden, M.R.; Goldberg, Y.P. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet., 2004, 36, 77-82.
68. Goswami, T.; Andrews, N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J. Biol. Chem., 2006, 281, 28494-28498.
69. Schmidt, P.J.; Toran, P.T.; Giannetti, A.M.; Bjorkman, P.J.; Andrews, N.C. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab., 2008, 7, 205-214.
70. Vujic Spasic, M.; Kiss, J.; Herrmann, T.; Galy, B.; Martinache, S.; Stolte, J.; Grone, H.J.; Stremmel, W.; Hentze, M.W.; Muckenthaler, M.U. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab., 2008, 7, 173-178.
71. Robb, A.; Wessling-Resnick, M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood, 2004, 104, 4294-4299.
72. Kawabata, H.; Yang, R.; Hirama, T.; Vuong, P.T.; Kawano, S.; Gombart, A.F.; Koeffler, H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem., 1999, 274, 20826-20832.
73. Waheed, A.; Britton, R.S.; Grubb, J.H.; Sly, W.S.; Fleming, R.E. HFE association with transferrin receptor 2 increases cellular uptake of transferrin-bound iron. Arch. Biochem. Biophys., 2008, 474, 193-197.
74. Ludwiczek, S.; Theurl, I.; Bahram, S.; Schumann, K.; Weiss, G. Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis. J. Cell Physiol., 2005, 204, 489-499.
75. Lin, L.; Goldberg, Y.P.; Ganz, T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood, 2005, 106, 2884-2889.
76. Babitt, J.L.; Huang, F.W.; Wrighting, D.M.; Xia, Y.; Sidis, Y.; Samad, T.A.; Campagna, J.A.; Chung, R.T.; Schneyer, A.L.; Woolf, C.J.; Andrews, N.C.; Lin, H.Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet., 2006, 38, 531-539.
77. Truksa, J.; Peng, H.; Lee, P.; Beutler, E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc. Natl. Acad. Sci. USA, 2006, 103, 10289-10293.
78. Babitt, J.L.; Huang, F.W.; Xia, Y.; Sidis, Y.; Andrews, N.C.; Lin, H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest., 2007, 117, 1933-1939.
79. Kuninger, D.; Kuns-Hashimoto, R.; Kuzmickas, R.; Rotwein, P. Complex biosynthesis of the muscle-enriched iron regulator RGMc. J. Cell Sci., 2006, 119, 3273-3283.
80. Finberg, K.E.; Heeney, M.M.; Campagna, D.R.; Aydinok, Y.; Pearson, H.A.; Hartman, K.R.; Mayo, M.M.; Samuel, S.M.; Strouse, J.J.; Markianos, K.; Andrews, N.C.; Fleming, M.D. Mutations in TMPRSS6 cause iron-refractory iron deficiency anaemia (IRIDA). Nat. Genet., 2008, 40, 569-571.
81. Melis, M.A.; Cau, M.; Congiu, R.; Sole, G.; Barella, S.; Cao, A.; Westerman, M.; Cazzola, M.; Galanello, R. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anaemia refractory to oral iron. Haematologica, 2008, 93, 1473-1479.
82. Guillem, F.; Lawson, S.; Kannengiesser, C.; Westerman, M.; Beaumont, C.; Grandchamp, B. Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anaemia and iron deficiency. Blood, 2008, 112, 2089-2091.
83. Du, X.; She, E.; Gelbart, T.; Truksa, J.; Lee, P.; Xia, Y.; Khovananth, K.; Mudd, S.; Mann, N.; Moresco, E.M.; Beutler, E.; Beutler, B. The serine protease TMPRSS6 is required to sense iron deficiency. Science, 2008, 320, 1088-1092.
84. Folgueras, A.R.; de Lara, F.M.; Pendas, A.M.; Garabaya, C.; Rodriguez, F.; Astudillo, A.; Bernal, T.; Cabanillas, R.; Lopez-Otin, C.; Velasco, G. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood, 2008, 112, 2539-2545.
85. Beutler, E. Iron storage disease: Facts, fiction and progress. Blood Cells Mol. Dis., 2007, 39, 140-147.
86. Babady, N.E.; Carelle, N.; Wells, R.D.; Rouault, T.A.; Hirano, M.; Lynch, D.R.; Delatycki, M.B.; Wilson, R.B.; Isaya, G.; Puccio, H. Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments. Mol. Genet. Metab., 2007, 92, 23-35.
87. Pietrangelo, A. The ferroportin disease. Blood Cells Mol. Dis., 2004, 32, 131-138.
88. Pietrangelo, A.; Caleffi, A.; Henrion, J.; Ferrara, F.; Corradini, E.; Kulaksiz, H.; Stremmel, W.; Andreone, P.; Garuti, C. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology, 2005, 128, 470-479.
89. Powell, L.W. Hereditary hemochromatosis and iron overload diseases. J. Gastroenterol. Hepatol., 2002, 17 Suppl, S191-195.
90. Adams, P.C.; Barton, J.C. Haemochromatosis. Lancet, 2007, 370, 1855-1860.
91. Wallace, D.F.; Subramaniam, V.N. Non-HFE haemochromatosis. World J. Gastroenterol., 2007, 13, 4690-4698.
92. Trinder, D.; Baker, E. Transferrin receptor 2: A new molecule in iron metabolism. Int. J. Biochem. Cell Biol., 2003, 35, 292-296.
93. Roetto, A.; Papanikolaou, G.; Politou, M.; Alberti, F.; Girelli, D.; Christakis, J.; Loukopoulos, D.; Camaschella, C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet., 2003, 33, 21-22.
94. Cemonesi, L.; Forni, G.L.; Soriani, N.; Lamagna, M.; Fermo, I.; Daraio, F.; Galli, A.; Pietra, D.; Malcovati, L.; Ferrari, M.; Camaschella, C.; Cazzola, M. Genetic and clinical heterogeneity of ferroportin disease. Br. J. Haematol., 2005, 131, 663-670.
95. Pietrangelo, A. Non-invasive assessment of hepatic iron overload: Are we finally there? J. Hepatol., 2005, 42, 153-154.
96. Gandon, Y.; Olivie, D.; Guyader, D.; Aube, C.; Oberti, F.; Sebille, V.; Deugnier, Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet, 2004, 363, 357-362.
97. Niederau, C.; Fischer, R.; Purschel, A.; Stremmel, W.; Haussinger, D.; Strohmeyer, G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology, 1996, 110, 1107-1119.
98. Tavill, A.S. Diagnosis and management of hemochromatosis. Hepatology, 2001, 33, 1321-1328.
99. Nielsen, P.; Fischer, R.; Buggisch, P.; Janka-Schaub, G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br. J. Haematol., 2003, 123, 952-953.
100. Weiss, G.; Goodnough, L.T. Anaemia of chronic disease. N. Engl. J. Med., 2005, 352, 1011-1023.
101. Kushner, J.P.; Porter, J.P.; Olivieri, N.F. Secondary iron overload. Hematol. Am. Soc. Hematol. Educ. Program, 2001, 47-61.
102. Gordeuk, V.R. African iron overload. Semin. Hematol., 2002, 39, 263-269.
103. Gordeuk, V.R.; Caleffi, A.; Corradini, E.; Ferrara, F.; Jones, R.A.; Castro, O.; Onyekwere, O.; Kittles, R.; Pignatti, E.; Montosi, G.; Garuti, C.; Gangaidzo, I.T.; Gomo, Z.A.; Moyo, V.M.; Rouault, T.A.; MacPhail, P.; Pietrangelo, A. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene small star, filled. Blood Cells Mol. Dis., 2003, 31, 299-304.
104. Porto, G.; De Sousa, M. Iron overload and immunity. World J. Gastroenterol., 2007, 13, 4707-4715.
105. Oppenheimer, S.J. Iron and its relation to immunity and infectious disease. J. Nutr., 2001, 131, 616S-633S; discussion 633S-635S.
106. Weiss, G.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Werner, E.R.; Werner-Felmayer, G.; Wachter, H. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp. Hematol., 1992, 20, 605-610.
107. Oexle, H.; Kaser, A.; Most, J.; Bellmann-Weiler, R.; Werner, E.R.; Werner-Felmayer, G.; Weiss, G. Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J. Leukoc. Biol., 2003, 74, 287-294.
108. Dlaska, M.; Weiss, G. Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression. J. Immunol., 1999, 162, 6171-6177.
109. Weiss, G.; Werner-Felmayer, G.; Werner, E.R.; Grunewald, K.; Wachter, H.; Hentze, M.W. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J. Exp. Med., 1994, 180, 969-976.
110. Recalcati, S.; Pometta, R.; Levi, S.; Conte, D.; Cairo, G. Response of monocyte iron regulatory protein activity to inflammation: Abnormal behavior in genetic hemochromatosis. Blood, 1998, 91, 2565-2572.
111. Schaible, U.E.; Kaufmann, S.H. Iron and microbial infection. Nat. Rev. Microbiol., 2004, 2, 946-953.
112. Nairz, M.; Fritsche, G.; Brunner, P.; Talasz, H.; Hantke, K.; Weiss, G. Interferon-gamma limits the availability of iron for intramacrophage Salmonella typhimurium. Eur. J. Immunol., 2008, 38, 1923-1936.
113. Thuma, P.E.; Weiss, G.; Herold, M.; Gordeuk, V.R. Serum neopterin, interleukin-4, and interleukin-6 concentrations in cerebral malaria patients and the effect of iron chelation therapy. Am. J. Trop. Med. Hyg., 1996, 54, 164-168.
114. Mencacci, A.; Cenci, E.; Boelaert, J.R.; Bucci, P.; Mosci, P.; Fe d'Ostiani, C.; Bistoni, F.; Romani, L. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J. Infect. Dis., 1997, 175, 1467-1476.
115. Weiss, G. [Iron, infection and anemia - a classical triad]. Wien. Klin. Wochenschr., 2002, 114, 357-367.
116. Weiss, G.; Thuma, P.E.; Mabeza, G.; Werner, E.R.; Herold, M.; Gordeuk, V.R. Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. J. Infect. Dis., 1997, 175, 226-230.
117. Weinberg, E.D. Iron availability and infection. Biochim. Biophys. Acta, 2008.
118. Weinberg, E.D. The role of iron in cancer. Eur. J. Cancer. Prev., 1996, 5, 19-36.
119. Hellerbrand, C.; Poppl, A.; Hartmann, A.; Scholmerich, J.; Lock, G. HFE C282Y heterozygosity in hepatocellular carcinoma: Evidence for an increased prevalence. Clin. Gastroenterol. Hepatol., 2003, 1, 279-284.
120. Moyo, V.M.; Gangaidzo, I.T.; Gordeuk, V.R.; Kiire, C.F.; Macphail, A.P. Tuberculosis and iron overload in Africa: A review. Cent. Afr. J. Med., 1997, 43, 334-339.
121. Arosio, P.; Levi, S. Ferritin, iron homeostasis, and oxidative damage. Free Radic. Biol. Med., 2002, 33, 457-463.
122. Torti, F.M.; Torti, S.V. Regulation of ferritin genes and protein. Blood, 2002, 99, 3505-3516.
123. Propper, R.D.; Cooper, B.; Rufo, R.R.; Nienhuis, A.W.; Anderson, W.F.; Bunn, H.F.; Rosenthal, A.; Nathan, D.G. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N. Engl. J. Med., 1977, 297, 418-423.
124. Hershko, C. Treating iron overload: The state of the art. Semin. Hematol., 2005, 42, S2-4.
125. Cario, H.; Janka-Schaub, G.; Janssen, G.; Jarisch, A.; Strauss, G.; Kohne, E. Recent developments in iron chelation therapy. Klin. Padiatr., 2007, 219, 158-165.
126. Porter, J.B. Concepts and goals in the management of transfusional iron overload. Am. J. Hematol., 2007, 82, 1136-1139
127. Maggio, A. Light and shadows in the iron chelation treatment of haematological diseases. Br. J. Haematol., 2007, 138, 407-421.
128. Fargion, S.; Mattioli, M.; Fracanzani, A.L.; Sampietro, M.; Tavazzi, D.; Fociani, P.; Taioli, E.; Valenti, L.; Fiorelli, G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 2448-2455.
129. Moirand, R.; Mendler, M.H.; Guillygomarc'h, A.; Brissot, P.; Deugnier, Y. Non-alcoholic steatohepatitis with iron: Part of insulin resistance-associated hepatic iron overload? J. Hepatol., 2000, 33, 1024-1026.
130. Uraz, S.; Aygun, C.; Sonsuz, A.; Ozbay, G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig. Dis. Sci., 2005, 50, 964-969.
131. Aigner, E.; Theurl, I.; Theurl, M.; Lederer, D.; Haufe, H.; Dietze, O.; Strasser, M.; Datz, C.; Weiss, G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am. J. Clin. Nutr., 2008, 87, 1374-1383.
132. Aigner, E.; Theurl, I.; Haufe, H.; Seifert, M.; Hohla, F.; Scharinger, L.; Stickel, F.; Mourlane, F.; Weiss, G.; Datz, C. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology, 2008, 135, 680-688.
133. Sumida, Y.; Kanemasa, K.; Fukumoto, K.; Yoshida, N.; Sakai, K.; Nakashima, T.; Okanoue, T. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol. Res., 2006, 36, 315-321.
134. Fletcher, L.M.; Dixon, J.L.; Purdie, D.M.; Powell, L.W.; Crawford, D.H. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology, 2002, 122, 281-289.
135. Harrison-Findik, D.D.; Schafer, D.; Klein, E.; Timchenko, N.A.; Kulaksiz, H.; Clemens, D.; Fein, E.; Andriopoulos, B.; Pantopoulos, K.; Gollan, J. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem., 2006, 281, 22974- 2982.
136. Weiss, G.; Umlauft, F.; Urbanek, M.; Herold, M.; Lovevsky, M.; Offner, F.; Gordeuk, V.R. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J. Infect. Dis., 1999, 180, 1452-1458.
137. Shedlofsky, S.I. Role of iron in the natural history and clinical course of hepatitis C disease. Hepatogastroenterology, 1998, 45, 349-355.
138. Drakesmith, H.; Prentice, A. Viral infection and iron metabolism. Nat. Rev. Microbiol., 2008, 6, 541-552.
139. Fujita, N.; Sugimoto, R.; Takeo, M.; Urawa, N.; Mifuji, R.; Tanaka, H.; Kobayashi, Y.; Iwasa, M.; Watanabe, S.; Adachi, Y.; Kaito, M. Hepcidin expression in the liver: Relatively low level in patients with chronic hepatitis C. Mol. Med., 2007, 13, 97-104.
140. Nishina, S.; Hino, K.; Korenaga, M.; Vecchi, C.; Pietrangelo, A.; Mizukami, Y.; Furutani, T.; Sakai, A.; Okuda, M.; Hidaka, I.; Okita, K.; Sakaida, I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology, 2008, 134, 226-238.
141. Fillebeen, C.; Muckenthaler, M.; Andriopoulos, B.; Bisaillon, M.; Mounir, Z.; Hentze, M.W.; Koromilas, A.E.; Pantopoulos, K. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J. Hepatol., 2007, 47, 12-22.
142. Theurl, I.; Zoller, H.; Obrist, P.; Datz, C.; Bachmann, F.; Elliott, R.M.; Weiss, G. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J. Infect. Dis., 2004, 190, 819-825.
143. Fillebeen, C.; Rivas-Estilla, A.M.; Bisaillon, M.; Ponka, P.; Muckenthaler, M.; Hentze, M.W.; Koromilas, A.E.; Pantopoulos, K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J. Biol. Chem., 2005, 280, 9049-9057.
144. Cho, H.; Lee, H.C.; Jang, S.K.; Kim, Y.K. Iron increases translation initiation directed by internal ribosome entry site of hepatitis C virus. Virus Genes, 2008, 37, 154-160.
145. Fujita, N.; Takei, Y. Iron, hepatitis C virus, and hepatocellular carcinoma: Iron reduction preaches the gospel for chronic hepatitis C. J. Gastroenterol., 2007, 42, 923-926.
146. Rulyak, S.J.; Eng, S.C.; Patel, K.; McHutchison, J.G.; Gordon, S.C.; Kowdley, K.V. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am. J. Gastroenterol., 2005, 100, 332-337.
147. Pietrangelo, A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology, 2003, 124, 1509-1523.
148. Nahon, P.; Sutton, A.; Rufat, P.; Ziol, M.; Thabut, G.; Schischmanoff, P.O.; Vidaud, D.; Charnaux, N.; Couvert, P.; Ganne-Carrie, N.; Trinchet, J.C.; Gattegno, L.; Beaugrand, M. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology, 2008, 134, 102-110.
149. Ludwiczek, S.; Aigner, E.; Theurl, I.; Weiss, G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood, 2003, 101, 4148-4154.
150. Mulero, V.; Brock, J.H. Regulation of iron metabolism in murine J774 macrophages: Role of nitric oxide-dependent and -independent pathways following activation with gamma interferon and lipopolysaccharide. Blood, 1999, 94, 2383-2389.
151. Byrd, T.F.; Horwitz, M.A. Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. J. Clin. Invest., 1993, 91, 969-976.
152. Weiss, G.; Bogdan, C.; Hentze, M.W. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J. Immunol., 1997, 158, 420-425.
153. Delaby, C.; Pilard, N.; Hetet, G.; Driss, F.; Grandchamp, B.; Beaumont, C.; Canonne-Hergaux, F. A physiological model to study iron recycling in macrophages. Exp. Cell Res., 2005, 310, 43-53.
154. Knutson, M.; Wessling-Resnick, M. Iron metabolism in the reticuloendothelial system. Crit. Rev. Biochem. Mol. Biol., 2003, 38, 61-88.
155. Roy, C.N.; Andrews, N.C. Anaemia of inflammation: The hepcidin link. Curr. Opin. Hematol., 2005, 12, 107-111.
156. Moldawer, L.L.; Marano, M.A.; Wei, H.; Fong, Y.; Silen, M.L.; Kuo, G.; Manogue, K.R.; Vlassara, H.; Cohen, H.; Cerami, A.; et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anaemia in vivo. FASEB J., 1989, 3, 1637-1643.
157. Nguyen, N.B.; Callaghan, K.D.; Ghio, A.J.; Haile, D.J.; Yang, F. Hepcidin expression and iron transport in alveolar macrophages. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 291, L417-425.
158. Laftah, A.H.; Ramesh, B.; Simpson, R.J.; Solanky, N.; Bahram, S.; Schumann, K.; Debnam, E.S.; Srai, S.K. Effect of hepcidin on intestinal iron absorption in mice. Blood, 2004, 103, 3940-3944.
159. Schroder, O.; Mickisch, O.; Seidler, U.; de Weerth, A.; Dignass, A.U.; Herfarth, H.; Reinshagen, M.; Schreiber, S.; Junge, U.; Schrott, M.; Stein, J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol., 2005, 100, 2503-2509.
160. Roy, C.N.; Custodio, A.O.; de Graaf, J.; Schneider, S.; Akpan, I.; Montross, L.K.; Sanchez, M.; Gaudino, A.; Hentze, M.W.; Andrews, N.C.; Muckenthaler, M.U. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat. Genet., 2004, 36, 481-485.
161. Theurl, I.; Mattle, V.; Seifert, M.; Mariani, M.; Marth, C.; Weiss, G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anaemia of chronic disease. Blood, 2006, 107, 4142-4148.
162. Jelkmann, W. Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res., 1998, 18, 555-559.
163. Means, R.T., Jr.; Krantz, S.B. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood, 1991, 78, 2564-2567
164. Taniguchi, S.; Dai, C.H.; Price, J.O.; Krantz, S.B. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood, 1997, 90, 2244-2252.
165. Punnonen, K.; Irjala, K.; Rajamaki, A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood, 1997, 89, 1052-1057.
166. Thomas, C.; Thomas, L. Anaemia of chronic disease: Pathophysiology and laboratory diagnosis. Lab. Hematol., 2005, 11, 14-23.
167. Wish, J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol., 2006, 1 Suppl 1, S4-8.
168. Tarng, D.C.; Huang, T.P. Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol. Dial. Transplant, 2002, 17, 1063-1069.
169. Guralnik, J.M.; Eisenstaedt, R.S.; Ferrucci, L.; Klein, H.G.; Woodman, R.C. Prevalence of anaemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood, 2004, 104, 2263-2268.
170. Murphy, S.T.; Parfrey, P.S. The impact of anaemia correction on cardiovascular disease in end-stage renal disease. Semin. Nephrol., 2000, 20, 350-355.
171. Gasche, C.; Lomer, M.C.; Cavill, I.; Weiss, G. Iron, anaemia, and inflammatory bowel diseases. Gut, 2004, 53, 1190-1197.
172. Weinberg, E.D. Iron loading and disease surveillance. Emerg. Infect. Dis., 1999, 5, 346-352.
173. Goodnough, L.T. Red cell growth factors in patients with chronic anemias. Curr. Hematol. Rep., 2002, 1, 119-123
174. Harding, A.E. Friedreich's ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain, 1981, 104, 589-620.
175. Mateo, I.; Llorca, J.; Volpini, V.; Corral, J.; Berciano, J.; Combarros, O. GAA expansion size and age at onset of Friedreich's ataxia. Neurology, 2003, 61, 274-275.
176. Mateo, I.; Llorca, J.; Volpini, V.; Corral, J.; Berciano, J.; Combarros, O. Expanded GAA repeats and clinical variation in Friedreich's ataxia. Acta Neurol. Scand., 2004, 109, 75-78.
177. Calabrese, V.; Lodi, R.; Tonon, C.; D'Agata, V.; Sapienza, M.; Scapagnini, G.; Mangiameli, A.; Pennisi, G.; Stella, A.M.; Butterfield, D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci., 2005, 233, 145-162.
178. Cabantchik, Z.I.; Breuer, W.; Zanninelli, G.; Cianciulli, P. LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol., 2005, 18, 277-287.
179. Lill, R.; Dutkiewicz, R.; Elsasser, H.P.; Hausmann, A.; Netz, D.J.; Pierik, A.J.; Stehling, O.; Urzica, E.; Muhlenhoff, U. Mechanisms of iron-sulfur protein maturation in mitochondria, cytosol and nucleus of eukaryotes. Biochim. Biophys. Acta, 2006, 1763, 652-667.
180. Gitlin, J.D. Aceruloplasminemia. Pediatr. Res., 1998, 44, 271-276.
181. Logan, J.I.; Harveyson, K.B.; Wisdom, G.B.; Hughes, A.E.; Archbold, G.P. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. QJM, 1994, 87, 663-670.
182. Levi, S.; Cozzi, A.; Arosio, P. Neuroferritinopathy: A neurodegenerative disorder associated with L-ferritin mutation. Best Pract. Res. Clin. Haematol., 2005, 18, 265-276.
183. Aguilar-Martinez, P.; Schved, J.F.; Brissot, P. The evaluation of hyperferritinemia: An updated strategy based on advances in detecting genetic abnormalities. Am. J. Gastroenterol., 2005, 100, 1185-1194.
184. Sheth, S.; Brittenham, G.M. Genetic disorders affecting proteins of iron metabolism: Clinical implications. Annu. Rev. Med., 2000, 51, 443-464.
185. Wong, K.; Barbin, Y.; Chakrabarti, S.; Adams, P. A point mutation in the iron-responsive element of the L-ferritin in a family with hereditary hyperferritinemia cataract syndrome. Can. J. Gastroenterol., 2005, 19, 253-255.
186. Hetet, G.; Devaux, I.; Soufir, N.; Grandchamp, B.; Beaumont, C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood, 2003, 102, 1904-1910.
187. Mackenzie, B.; Takanaga, H.; Hubert, N.; Rolfs, A.; Hediger, M.A. Functional properties of multiple isoforms of human divalent metal-ion transporter 1 (DMT1). Biochem. J., 2007, 403, 59-69.
188. Lam-Yuk-Tseung, S.; Gros, P. Distinct Targeting and Recycling Properties of Two Isoforms of the Iron Transporter DMT1 (NRAMP2, Slc11A2)(dagger). Biochemistry, 2006, 45, 2294-2301.
189. Xu, H.; Jin, J.; DeFelice, L.J.; Andrews, N.C.; Clapham, D.E. A spontaneous, recurrent mutation in divalent metal transporter-1 exposes a calcium entry pathway. PLoS Biol., 2004, 2, E50.
190. Oudit, G.Y.; Sun, H.; Trivieri, M.G.; Koch, S.E.; Dawood, F.; Ackerley, C.; Yazdanpanah, M.; Wilson, G.J.; Schwartz, A.; Liu, P.P.; Backx, P.H. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med., 2003, 9, 1187-1194.
191. Wetli, H.A.; Buckett, P.D.; Wessling-Resnick, M. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem. Biol., 2006, 13, 965-972.
192. Rivera, S.; Nemeth, E.; Gabayan, V.; Lopez, M.A.; Farshidi, D.; Ganz, T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood, 2005, 106, 2196-2199.
193. Niederkofler, V.; Salie, R.; Arber, S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest., 2005, 115, 2180-2186.
194. Yu, P.B.; Hong, C.C.; Sachidanandan, C.; Babitt, J.L.; Deng, D.Y.; Hoyng, S.A.; Lin, H.Y.; Bloch, K.D.; Peterson, R.T. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol., 2008, 4, 33-41.
195. Tobin, J.F.; Celeste, A.J. Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. Drug Discov. Today, 2006, 11, 405-411
196. Xiao, Y.T.; Xiang, L.X.; Shao, J.Z. Bone morphogenetic protein. Biochem. Biophys. Res. Commun., 2007, 362, 550-553
197. Hutchinson, C.; Geissler, C.; Powell, J.; Bomford, A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut, 2007, 56, 1291-5.
198. Golubov, J.; Flanagan, P.; Adams, P. Inhibition of iron absorption by omeprazole in rat model. Dig. Dis. Sci., 1991, 36, 405-408.
199. Mair, S.; Ludwiczek, S.; Muckenthaler, M.; Schwelberger, H.; Theurl, I.; Weiss, H.; Hentze, M.W.; Ritter, M.; Weiss, G. Omeprazole decreases duodenal iron absorption via inhibition of DMT-1 function. Am. J. Hematol., 2007, 82, 583.
200. Boddaert, N.; Le Quan Sang, K.H.; Rotig, A.; Leroy-Willig, A.; Gallet, S.; Brunelle, F.; Sidi, D.; Thalabard, J.C.; Munnich, A.; Cabantchik, Z.I. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood, 2007, 110, 401-408
201. Sohn, Y.S.; Breuer, W.; Munnich, A.; Cabantchik, Z.I. Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications. Blood, 2008, 111, 1690-1699.
202. Wang, G.L.; Semenza, G.L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNAbinding activity: implications for models of hypoxia signal transduction. Blood, 1993, 82, 3610-3615.
203. Sturm, B.; Stupphann, D.; Kaun, C.; Boesch, S.; Schranzhofer, M.; Wojta, J.; Goldenberg, H.; Scheiber-Mojdehkar, B. Recombinant human erythropoietin: Effects on frataxin expression in vitro. Eur. J. Clin. Invest., 2005, 35, 711-717.
204. Boesch, S.; Sturm, B.; Hering, S.; Goldenberg, H.; Poewe, W.; Scheiber-Mojdehkar, B. Friedreich's ataxia: Clinical pilot trial with recombinant human erythropoietin. Ann. Neurol., 2007, 62, 521-524.
205. Lee, P.; Peng, H.; Gelbart, T.; Beutler, E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc. Natl. Acad. Sci. USA, 2004, 101, 9263-9265
206. Kawabata, H.; Tomosugi, N.; Kanda, J.; Tanaka, Y.; Yoshizaki, K.; Uchiyama, T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica, 2007, 92, 857-858.
207. Laftah, A.H.; Sharma, N.; Brookes, M.J.; McKie, A.T.; Simpson, R.J.; Iqbal, T.H.; Tselepis, C. Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem. J., 2006, 397, 61-67.
208. Manalo, D.J.; Rowan, A.; Lavoie, T.; Natarajan, L.; Kelly, B.D.; Ye, S.Q.; Garcia, J.G.; Semenza, G.L. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood, 2005, 105, 659-669.
209. Semenza, G.L.; Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol., 1992, 12, 5447-5454.
210. Iyer, N.V.; Kotch, L.E.; Agani, F.; Leung, S.W.; Laughner, E.; Wenger, R.H.; Gassmann, M.; Gearhart, J.D.; Lawler, A.M.; Yu, A.Y.; Semenza, G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev., 1998, 12, 149-162.
211. Yu, A.Y.; Shimoda, L.A.; Iyer, N.V.; Huso, D.L.; Sun, X.; McWilliams, R.; Beaty, T.; Sham, J.S.; Wiener, C.M.; Sylvester, J.T.; Semenza, G.L. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J. Clin. Invest., 1999, 103, 691-696.
212. Pinto, J.P.; Ribeiro, S.; Pontes, H.; Thowfeequ, S.; Tosh, D.; Carvalho, F.; Porto, G. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signalling and regulation of C/EBP{alpha}. Blood, 2008, 111, 5727-5788.
213. Tanno, T.; Bhanu, N.V.; Oneal, P.A.; Goh, S.H.; Staker, P.; Lee, Y.T.; Moroney, J.W.; Reed, C.H.; Luban, N.L.; Wang, R.H.; Eling, T.E.; Childs, R.; Ganz, T.; Leitman, S.F.; Fucharoen, S.; Miller, J.L. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med., 2007, 13, 1096-1101.
214. Pak, M.; Lopez, M.A.; Gabayan, V.; Ganz, T.; Rivera, S. Suppression of hepcidin during anaemia requires erythropoietic activity. Blood, 2006, 108, 3730-3735.
215. Weiss, G.; Houston, T.; Kastner, S.; Johrer, K.; Grunewald, K.; Brock, J.H. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood, 1997, 89, 680-687.
216. Busfield, S.J.; Tilbrook, P.A.; Callus, B.A.; Spadaccini, A.; Kuhn, L.; Klinken, S.P. Complex regulation of transferrin receptors during erythropoietin-induced differentiation of J2E erythroid cells - elevated transcription and mRNA stabilisation produce only a modest rise in protein content. Eur. J. Biochem., 1997, 249, 77-84.
217. Zhu, B.M.; McLaughlin, S.K.; Na, R.; Liu, J.; Cui, Y.; Martin, C.; Kimura, A.; Robinson, G.W.; Andrews, N.C.; Hennighausen, L. Hematopoietic-specific Stat5-null mice display microcytic hypochromic anaemia associated with reduced transferrin receptor gene expression. Blood, 2008, 112, 2071-2080.
218. Kerenyi, M.A.; Grebien, F.; Gehart, H.; Schifrer, M.; Artaker, M.; Kovacic, B.; Beug, H.; Moriggl, R.; Mullner, E.W. Stat 5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood, 2008, 112, 3878-3888.
219. Zoller, H.; Decristoforo, C.; Weiss, G. Erythroid 5-aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-dependent regulation. Br. J. Haematol., 2002, 118, 619-626.